On August 20, 2024 Phigenix reported that United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,064,403, which relates to compositions and methods related to the use and administration of certain PAX2 inhibitors for treating drug-resistant breast cancer previously treated with an anti-estrogen receptor, anti-progesterone receptor, or an anti-her2 drug (Press release, Phigenix, AUG 20, 2024, https://www.phigenix.com/news/2024/8/20/phigenix-inc-receives-issuance-of-us-patent-covering-novel-therapeutic-for-treating-drug-resistant-breast-cancer [SID1234646009]). Dr. Carlton D. Donald, President and CEO of PHIGENIX, commented, "We are extremely pleased to receive this new patent as we continue to innovate new drugs for patients with hard-to-treat cancers."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!